Life Spine announced today that the company has successfully completed initial cases with the OCTAVE Posterior Fusion System, which is intended for attachment to the spinous processes for the purpose of achieving fusion in conjunction with bone graft. The U.S. Food and Drug Administration (FDA) provided 510(k) marketing clearance to the OCTAVE System last month.
The unique implant core design maximizes graft containment volume while the aggressive fixation spikes allow for increased stability between the spinous process and the implant.
OCTAVE is the sixteenth product family brought to market to date by Life Spine, and the response to the initial OCTAVE surgeries has been the best in Life Spine’s history.
Life Spine is dedicated to improving the quality of life for spinal patients by increasing procedural efficiency and efficacy through innovative design, uncompromising quality standards, and the most technologically advanced manufacturing platforms. Life Spine, which is privately held, is based in Hoffman Estates, Illinois.
Source: Life Spine